Last reviewed · How we verify

Midazolam+Ketamine Combination

Universidad de Cartagena · FDA-approved active Small molecule

Midazolam and ketamine together produce sedation and anesthesia by enhancing GABAergic inhibition and blocking NMDA glutamate receptors, respectively.

Midazolam and ketamine together provide sedation and anesthesia by enhancing GABAergic inhibition and blocking NMDA receptors, respectively. Used for Procedural sedation and anesthesia, Emergency sedation, Induction of general anesthesia.

At a glance

Generic nameMidazolam+Ketamine Combination
Also known asMidazolam, Ketamine hydrochloride
SponsorUniversidad de Cartagena
Drug classSedative-hypnotic and dissociative anesthetic combination
TargetGABA-A receptor (midazolam); NMDA receptor (ketamine)
ModalitySmall molecule
Therapeutic areaAnesthesia and Sedation
PhaseFDA-approved

Mechanism of action

Midazolam is a benzodiazepine that potentiates GABA-A receptor signaling in the central nervous system, producing anxiolysis and sedation. Ketamine is an NMDA receptor antagonist that produces dissociative anesthesia and analgesia. The combination leverages synergistic effects for enhanced sedation and anesthesia with potentially reduced individual drug requirements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results